ABCG2: the key to chemoresistance in cancer stem cells?

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66
   PubMed Web of Science ®Google Scholar
• Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008;26(17):2871-5
   PubMed Web of Science ®Google Scholar
• Hwang IT, Chung YM, Kim JJ, Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun 2007;359(2):304-10
   PubMed Web of Science ®Google Scholar
• Song J, Shih Ie M, Salani R, Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 2007;13(22 Pt 1):6842-9
   PubMed Web of Science ®Google Scholar
• Liu F, Xie ZH, Cai GP, Jiang YY. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull 2007;30(12):2279-83
   PubMed Web of Science ®Google Scholar
• Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006;86(12):1203-7
   PubMed Web of Science ®Google Scholar
• Dallas NA, Xia L, Fan F, Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69(5):1951-7
   PubMed Web of Science ®Google Scholar
• Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 2009 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99(1):319-25
   PubMed Web of Science ®Google Scholar
• Bleau AM, Hambardzumyan D, Ozawa T, PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4(3):226-35
   PubMed Web of Science ®Google Scholar
• Tirino V, Desiderio V, d'Aquino R, Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008;3(10):e3469
   PubMedGoogle Scholar
• Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008;268(1):1-9
   PubMed Web of Science ®Google Scholar
• Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59(17):4237-41
   PubMed Web of Science ®Google Scholar
• Zen Y, Fujii T, Yoshikawa S, Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007;170(5):1750-62
   PubMed Web of Science ®Google Scholar
• Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58(7):931-59
   PubMed Web of Science ®Google Scholar
• Ozvegy C, Litman T, Szakacs G, Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285(1):111-7
   PubMed Web of Science ®Google Scholar
• Bram E, Ifergan I, Shafran A, Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol 2006;58(6):826-34
   PubMed Web of Science ®Google Scholar
• Shafran A, Ifergan I, Bram E, ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 2005;65(18):8414-22
   PubMed Web of Science ®Google Scholar
• Morisaki K, Robey RW, Ozvegy-Laczka C, Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005;56(2):161-72
   PubMed Web of Science ®Google Scholar
• Zhou S, Morris JJ, Barnes Y, Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 2002;99(19):12339-44
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Utsunomiya T, Inoue H, Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006;24(3):506-13
   PubMed Web of Science ®Google Scholar
• Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8(5):411-24
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95(26):15665-70
   PubMed Web of Science ®Google Scholar
• Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005;37(4):720-5
   PubMed Web of Science ®Google Scholar
• Kim M, Turnquist H, Jackson J, The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002;8(1):22-8
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Ross DD, Nakanishi T, The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004;279(23):24218-25
   PubMed Web of Science ®Google Scholar
• Susanto J, Lin YH, Chen YN, Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells. PLoS One 2008;3(12):e4023
   PubMedGoogle Scholar
• Lopez JP, Wang-Rodriguez J, Chang CY, Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 2008;118(8):1372-6
   PubMed Web of Science ®Google Scholar
• Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans 2005;33(Pt 1):241-5
   PubMedGoogle Scholar
• Diestra JE, Scheffer GL, Catala I, Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198(2):213-9
   PubMed Web of Science ®Google Scholar
• Abbott BL, Colapietro AM, Barnes Y, Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100(13):4594-601
   PubMed Web of Science ®Google Scholar
• Galimberti S, Guerrini F, Palumbo GA, Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res 2004;28(4):367-72
   PubMed Web of Science ®Google Scholar
• van der Kolk DM, Vellenga E, Scheffer GL, Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002;99(10):3763-70
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat AM, Sayada L, Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10(23):7896-902
   PubMed Web of Science ®Google Scholar
• Kanzaki A, Toi M, Nakayama K, Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001;92(4):452-8
   PubMedGoogle Scholar
• Burger H, Foekens JA, Look MP, RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9(2):827-36
   PubMed Web of Science ®Google Scholar
• Yoh K, Ishii G, Yokose T, Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004;10(5):1691-7
   PubMed Web of Science ®Google Scholar
• Friedrich RE, Punke C, Reymann A. Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma. In Vivo 2004;18(2):133-47
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Diestra JE, Condom E, Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer 2003;88(6):879-86
   PubMed Web of Science ®Google Scholar
• Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007;1(3):241-2
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66(19):9339-44
   PubMedGoogle Scholar
• Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006;124(6):1111-5
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3(7):730-7
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983-8
   PubMed Web of Science ®Google Scholar
• O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445(7123):106-10
   PubMed Web of Science ®Google Scholar
• Dalerba P, Dylla SJ, Park IK, Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104(24):10158-63
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, Identification of human brain tumour initiating cells. Nature 2004;432(7015):396-401
   PubMed Web of Science ®Google Scholar
• Li C, Heidt DG, Dalerba P, Identification of pancreatic cancer stem cells. Cancer Res 2007;67(3):1030-7
   PubMed Web of Science ®Google Scholar
• Prince ME, Sivanandan R, Kaczorowski A, Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104(3):973-8
   PubMed Web of Science ®Google Scholar
• Alvi AJ, Clayton H, Joshi C, Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003;5(1):R1-8
   PubMed Web of Science ®Google Scholar
• Summer R, Kotton DN, Sun X, Side population cells and Bcrp1 expression in lung. Am J Physiol Lung Cell Mol Physiol 2003;285(1):L97-104
   PubMed Web of Science ®Google Scholar
• Du Y, Funderburgh ML, Mann MM, Multipotent stem cells in human corneal stroma. Stem Cells 2005;23(9):1266-75
   PubMed Web of Science ®Google Scholar
• Hussain SZ, Strom SC, Kirby MR, Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig Dis Sci 2005;50(10):1755-63
   PubMed Web of Science ®Google Scholar
• Goodell MA, Rosenzweig M, Kim H, Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997;3(12):1337-45
   PubMed Web of Science ®Google Scholar
• Kruger JA, Kaplan CD, Luo Y, Characterization of stem cell-like cancer cells in immune-competent mice. Blood 2006;108(12):3906-12
   PubMed Web of Science ®Google Scholar
• Mitsutake N, Iwao A, Nagai K, Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007;148(4):1797-803
   PubMed Web of Science ®Google Scholar
• Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006;103(30):11154-9
   PubMed Web of Science ®Google Scholar
• Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004;101(3):781-6
   PubMed Web of Science ®Google Scholar
• Shimano K, Satake M, Okaya A, Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol 2003;163(1):3-9
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101(39):14228-33
   PubMed Web of Science ®Google Scholar
• Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99(2):507-12
   PubMed Web of Science ®Google Scholar
• Ee PL, Kamalakaran S, Tonetti D, Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 2004;64(4):1247-51
   PubMed Web of Science ®Google Scholar
• Wang H, Lee EW, Zhou L, Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol 2008;73(3):845-54
   PubMed Web of Science ®Google Scholar
• Szatmari I, Vamosi G, Brazda P, Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 2006;281(33):23812-23
   PubMed Web of Science ®Google Scholar
• Yasuda S, Itagaki S, Hirano T, Iseki K. Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J Pharm Pharm Sci 2006;9(1):133-9
   PubMed Web of Science ®Google Scholar
• Imai Y, Ishikawa E, Asada S, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005;65(2):596-604
   PubMed Web of Science ®Google Scholar
• Wang H, Unadkat JD, Mao Q. Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res 2008;25(2):444-52
   PubMed Web of Science ®Google Scholar
• To KK, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 2006;26(22):8572-85
   PubMed Web of Science ®Google Scholar
• Mogi M, Yang J, Lambert JF, Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 2003;278(40):39068-75
   PubMed Web of Science ®Google Scholar
• Steelman LS, Stadelman KM, Chappell WH, Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12(9):1139-65
   PubMed Web of Science ®Google Scholar
• Steelman LS, Abrams SL, Whelan J, Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22(4):686-707
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12(18):5268-72
   PubMed Web of Science ®Google Scholar
• Takada T, Suzuki H, Gotoh Y, Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 2005;33(7):905-9
   PubMed Web of Science ®Google Scholar
• Hu C, Li H, Li J, Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008;29(12):2289-97
   PubMed Web of Science ®Google Scholar
• Chen JS, Pardo FS, Wang-Rodriguez J, EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 2006;116(3):401-6
   PubMed Web of Science ®Google Scholar
• Yin L, Castagnino P, Assoian RK. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res 2008;68(3):800-7
   PubMed Web of Science ®Google Scholar
• Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 2006;6(4):358-65
   Web of Science ®Google Scholar
• Ivetac I, Gurung R, Hakim S, Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. EMBO Rep 2009;10(5):487-93
   PubMed Web of Science ®Google Scholar
• Lemos C, Kathmann I, Giovannetti E, Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer 2008;123(7):1712-20
   PubMed Web of Science ®Google Scholar
• To KK, Polgar O, Huff LM, Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 2008;6(1):151-64
   PubMed Web of Science ®Google Scholar
• To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3′ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008;28(17):5147-61
   PubMed Web of Science ®Google Scholar
• Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009;75(6):1374-9
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5(4):275-84
   PubMed Web of Science ®Google Scholar
• Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13(16):2059-63
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10(5):470-81
   PubMed Web of Science ®Google Scholar
• Rabindran SK, He H, Singh M, Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998;58(24):5850-8
   PubMed Web of Science ®Google Scholar
• Woehlecke H, Osada H, Herrmann A, Lage H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int J Cancer 2003;107(5):721-8
   PubMed Web of Science ®Google Scholar
• Robey RW, Polgar O, Deeken J, ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007;26(1):39-57
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Dean M, A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 2006;11(2):176-83
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004;64(4):1242-6
   PubMed Web of Science ®Google Scholar
• Elkind NB, Szentpetery Z, Apati A, Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005;65(5):1770-7
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Boersma AW, Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104(9):2940-2
   PubMed Web of Science ®Google Scholar
• Ongkeko WM, An Y, Chu TS, Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents. Laryngoscope 2006;116(8):1390-6
   PubMed Web of Science ®Google Scholar
• Yanase K, Tsukahara S, Asada S, Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004;3(9):1119-25
   PubMed Web of Science ®Google Scholar
• Chu TS, Chen JS, Lopez JP, Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2008;134(9):979-84
   PubMed Web of Science ®Google Scholar
• Liu W, Baer MR, Bowman MJ, The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007;13(8):2463-70
   PubMed Web of Science ®Google Scholar
• Mukai M, Che XF, Furukawa T, Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci 2003;94(6):557-63
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108(2):678-84
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64(7):2333-7
   PubMed Web of Science ®Google Scholar
• McDevitt CA, Crowley E, Hobbs G, Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2? FEBS J 2008;275(17):4354-62
   PubMed Web of Science ®Google Scholar
• Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108(4):1370-3
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21(6):1267-75
   PubMed Web of Science ®Google Scholar
• Shukla S, Sauna ZE, Ambudkar SV. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 2008;22(2):445-7
   PubMed Web of Science ®Google Scholar
• Breedveld P, Pluim D, Cipriani G, The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65(7):2577-82
   PubMed Web of Science ®Google Scholar
• Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 2007;102(6):1749-57
   PubMed Web of Science ®Google Scholar
• Lopez JP, Wang-Rodriguez J, Chang C, Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg 2007;133(10):1022-7
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Oka M, Soda H, Gefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65(4):1541-6
   PubMed Web of Science ®Google Scholar
• Li HZ, Yi TB, Wu ZY. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer 2008;8:135
   PubMed Web of Science ®Google Scholar
• Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008;27(47):6120-30
   PubMed Web of Science ®Google Scholar
• Diop NK, Hrycyna CA. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 2005;44(14):5420-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6(10):834-48
   PubMed Web of Science ®Google Scholar
• Erlichman C, Boerner SA, Hallgren CG, The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61(2):739-48
   PubMed Web of Science ®Google Scholar
• Wang-Rodriguez J, Lopez JP, Altuna X, STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 2006;116(8):1409-16
   PubMed Web of Science ®Google Scholar
• Servidei T, Riccardi A, Sanguinetti M, Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 2006;208(1):220-8
   PubMed Web of Science ®Google Scholar
• Kim DW, Lee SK, Chu K, Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 2009;84(1):86-90
   PubMed Web of Science ®Google Scholar
• Muller PJ, Dally H, Klappenecker CN, Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 2009;124(7):1669-74
   PubMed Web of Science ®Google Scholar
• Chen YN, Mickley LA, Schwartz AM, Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265(17):10073-80
   PubMed Web of Science ®Google Scholar
• Robey RW, Honjo Y, Morisaki K, Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003;89(10):1971-8
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22(47):7340-58
   PubMed Web of Science ®Google Scholar
• Kellner U, Hutchinson L, Seidel A, Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer 1997;71(5):817-24
   PubMed Web of Science ®Google Scholar
• Brangi M, Litman T, Ciotti M, Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59(23):5938-46
   PubMed Web of Science ®Google Scholar
• Robey RW, Medina-Perez WY, Nishiyama K, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001;7(1):145-52
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Doyle LA, Hassel B, Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 2003;64(6):1452-62
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Schneider E, Dixon KH, Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992;52(22):6175-81
   PubMed Web of Science ®Google Scholar
• Allen JD, Van Dort SC, Buitelaar M, Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003;63(6):1339-44
   PubMed Web of Science ®Google Scholar
• Yang CJ, Horton JK, Cowan KH, Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 1995;55(18):4004-9
   PubMed Web of Science ®Google Scholar
• Maliepaard M, van Gastelen MA, Tohgo A, Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7(4):935-41
   PubMed Web of Science ®Google Scholar
• Schellens JH, Maliepaard M, Scheper RJ, Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000;922:188-94
   PubMed Web of Science ®Google Scholar
• Ishii M, Iwahana M, Mitsui I, Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 2000;11(5):353-62
   PubMed Web of Science ®Google Scholar
• Volk EL, Farley KM, Wu Y, Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62(17):5035-40
   PubMed Web of Science ®Google Scholar
• Mitomo H, Kato R, Ito A, A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 2003;373(Pt 3):767-74
   PubMedGoogle Scholar
• Chen ZS, Robey RW, Belinsky MG, Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63(14):4048-54
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Ikegami Y, Sano K, Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 2004;4(1):25-35
   PubMedGoogle Scholar
• Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63(17):5538-43
   PubMed Web of Science ®Google Scholar
• Nakatomi K, Yoshikawa M, Oka M, Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001;288(4):827-32
   PubMed Web of Science ®Google Scholar
• Xiao Y, Davidson R, Smith A, A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 2006;3(1):45-54
   PubMedGoogle Scholar
• Ozvegy-Laczka C, Hegedus T, Varady G, High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65(6):1485-95
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Wang SR, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78(2):153-61
   PubMed Web of Science ®Google Scholar
• Katayama K, Shibata K, Mitsuhashi J, Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling. Anticancer Res 2009;29(4):1059-65
   PubMed Web of Science ®Google Scholar
• Shi Z, Peng XX, Kim IW, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67(22):11012-20
   PubMed Web of Science ®Google Scholar
• Suvannasankha A, Minderman H, O'Loughlin KL, Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 2004;127(4):392-8
   PubMed Web of Science ®Google Scholar
• Sargent JM, Williamson CJ, Maliepaard M, Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 2001;115(2):257-62
   PubMed Web of Science ®Google Scholar
• van der Pol MA, Broxterman HJ, Pater JM, Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 2003;88(2):134-47
   PubMedGoogle Scholar
• Diestra JE, Condom E, Del Muro XG, Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol 2003;170(4 Pt 1):1383-7
   PubMed Web of Science ®Google Scholar
• Faneyte IF, Kristel PM, Maliepaard M, Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002;8(4):1068-74
   PubMed Web of Science ®Google Scholar
• Kawabata S, Oka M, Soda H, Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003;9(8):3052-7
   PubMed Web of Science ®Google Scholar
• Deichmann M, Thome M, Egner U, The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin. J Cutan Pathol 2005;32(7):467-73
   PubMed Web of Science ®Google Scholar
• Konig J, Hartel M, Nies AT, Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 2005;115(3):359-67
   PubMed Web of Science ®Google Scholar
• Bart J, Hollema H, Groen HJ, The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 2004;40(14):2064-70
   PubMed Web of Science ®Google Scholar